Immunotherapy Drugs Market Size & Market Analysis

The global immunotherapy drugs market size was valued at USD 110.55 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.92% from 2022 to 2030. The market is primarily driven by the rising incidence of chronic diseases globally, like diabetes. 

For instance, in March 2022, Nextera AS strategically collaborated with Zelluna Immunotherapy AS for the development of optimized TCRs for cancer immunotherapy. Furthermore, in February 2022, Biomunex Pharmaceuticals collaborated with Institut Curie for the development of an immunotherapy drug candidate for treating hematological malignancies using Biomunex Pharmaceuticals’ BiXAR technology. Moreover, in January 2021, Boehringer Ingelheim International GmbH signed a licensing agreement with Enara Bio for novel cancer immunotherapies by utilizing Enara Bio’s Dark Antigen discovery platform.

In addition, the high adoption of biosimilar drugs in immunotherapy is anticipated to boost growth in market dynamics. For instance, Abevmy, a biosimilar of Avastin, was launched by Biocon Biologics and Viatris Inc. in Canada across four oncology indications, in May 2022. Furthermore, the European Medicines Agency (EMA) accepted the Sandoz application for high concentration formulation of its biosimilar Hyrimoz (adalimumab) indicated for rheumatoid arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis. These developments are expected to drive industry growth.

Conversely, high attrition rates and high costs associated with immunotherapy treatment are projected to impede industry growth. According to the American Society of Clinical Oncology, immunotherapy launched between 2009 and 2014 costs above USD 100,000 annually. Moreover, CAR T-cell therapy costs up to approximately USD 500,000 annually. In addition, as per the NCBI, anti-cancer drug prices are two times higher in the U.S. than in Europe.

North America dominated the global industry in 2021 and accounted for the largest share of more than 44.90% of the overall revenue. The launch and regulatory approval of new immunotherapy drugs and favorable reimbursement policies are projected to aid in the region’s growth. For instance, Keytruda, Merck’s anti-PD-1 therapy, was approved by the FDA in October 2021, in combination with chemotherapy for cervical cancer treatment. Moreover, in August 2021, Opdivo (nivolumab) manufactured by Bristol Myers Squibb Co. received FDA approval for the treatment of urothelial carcinoma.

The leading players are focusing on growth strategies, such as innovations in the existing products, approval of new products, and mergers & acquisitions, to gain higher market shares. For instance, in January 2021, Sanofi entered an agreement with Kymab to acquire the company for an upfront payment of about USD 1.1 billion, resulting in the addition of KY1005, a monoclonal antibody, into its pipeline. Some of the prominent players in the global immunotherapy drugs market include:

  • Amgen, Inc.
  • Novartis AG
  • AbbVie, Inc.
  • Pfizer, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • AstraZeneca
  • GSK
  • Sanofi
  • Bayer AG

On the basis of drug types, the industry has been further categorized into cancer, autoimmune diseases, infectious diseases, and others. The cancer segment accounted for the largest revenue share of more than 91.10% in 2021 owing to the increased prevalence of cancer, coupled with a rise in the launch of cancer immunotherapies. As per Globocan 2020, breast cancer and lung cancer are the two most predominant cancers with a prevalence of approximately 11.7% and 11.4%. Moreover, in April 2021, the FDA approved Opdivo (nivolumab) in combination with chemotherapy for patients with gastric cancer.

On the other hand, the autoimmune diseases segment is anticipated to register the fastest growth rate during the forecast period. The growth of this segment can be attributed to the increasing cases of autoimmune diseases across the globe and regional approvals of immunotherapy drugs. As per NCBI research, the estimated global prevalence of rheumatoid arthritis is around 0.46% of the global population. Moreover, GSK’s Benlysta (belimumab) received China’s National Medical Products Administration approval for the treatment of active lupus nephritis in February 2022.

Source : https://www.grandviewresearch.com/industry-analysis/immunotherapy-drugs-market-report

Cancer Immunotherapy Market Size & Market Analysis

The global cancer immunotherapy market was valued at USD 104.96 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.2% from 2022 to 2030. Increasing prevalence of oncology across the globe coupled with a surge in R&D efforts for the development of novel oncology therapeutics are the major driving factors for the market. Moreover, the presence of various organizations that support immunotherapy research is also expected to fuel market growth. The most common type of malignancies affecting the U.S. population is breast, prostate, lung, and colorectal. In addition, according to the Cancer Council, Australia reported 150,000  new cancer cases with 50,000 deaths in 2020. Thus, the surge in prevalence of malignant tumor cases is anticipated to accelerate market expansion in the coming years.

The presence of various government and non-government organizations that create awareness and promote research is augmenting market expansion. For instance, Cancer Research Institute funded more than 120 clinical trials and invested around USD 474 million in research. Moreover, the Society for Immunotherapy of Cancer(SITC) is engaged in improving patient outcomes by advancing the science and application of oncology immunotherapy. These organizations are working with scientists and researchers to discover novel treatment regimens of immune therapy.

Cancer Immunotherapy Market Size & Market Analysis

Furthermore, increasing funding for the development of novel treatments is expected to boost R&D activities to develop cancer immunotherapy. For instance, in June 2022, a group of Stanford scientists received funding of USD 13 million from Cancer Grand Challenges, a funding initiative by Cancer Research UK and the U.S. National Cancer Institute. This funding is awarded for the development of next-generation immunotherapies, the study of extrachromosomal DNA, and the investigation of early-stage malignancies.

Increasing approval of novel immunotherapies is anticipated to propel the market growth over the forecast period. During 2020-2022, the U.S. FDA has approved various anti-PD-1/L1 antibodies such as nivolumab, atezolizumab, avelumab, dostarlimab, and others for the treatment of NSCLC, renal cell carcinoma, melanoma, breast, prostate malignancies, and others. The higher approvals of immunotherapeutic agents have propelled the market growth.

Various Strategic initiatives undertaken by leading players are also expected to facilitate the market demand. For instance, in August 2022,  BioNTech SE and Genmab A/S expanded their strategic collaboration for the development and launch of new immune therapies for the treatment of various cancer forms. Moreover, in March 2022,  Merck & Co., Inc announced the approval of KEYTRUDA from the U.S. FDA. KEYTRUDA is an anti-PD-1 therapy for the treatment of advanced endometrial carcinoma.

However, side effects associated with immunotherapy are likely to hamper the prescription rate for cancer treatment. The available therapies are associated with several adverse effects, such as pain, insomnia, fatigue, nausea, and gastrointestinal conditions. These adverse effects impact the overall quality of life of patients and the management of these adverse effects incurs extra costs. In addition, prolonged consumption of immunotherapeutic drugs may cause severe damage to the organs and increase the incidence of organ failure cases.

The presence of various government and non-government organizations that create awareness and promote research is augmenting market expansion. For instance, Cancer Research Institute funded more than 120 clinical trials and invested around USD 474 million in research. Moreover, the Society for Immunotherapy of Cancer(SITC) is engaged in improving patient outcomes by advancing the science and application of oncology immunotherapy. These organizations are working with scientists and researchers to discover novel treatment regimens of immune therapy.

Cancer Immunotherapy Market Size & Market Analysis

Furthermore, increasing funding for the development of novel treatments is expected to boost R&D activities to develop cancer immunotherapy. For instance, in June 2022, a group of Stanford scientists received funding of USD 13 million from Cancer Grand Challenges, a funding initiative by Cancer Research UK and the U.S. National Cancer Institute. This funding is awarded for the development of next-generation immunotherapies, the study of extrachromosomal DNA, and the investigation of early-stage malignancies.

Increasing approval of novel immunotherapies is anticipated to propel the market growth over the forecast period. During 2020-2022, the U.S. FDA has approved various anti-PD-1/L1 antibodies such as nivolumab, atezolizumab, avelumab, dostarlimab, and others for the treatment of NSCLC, renal cell carcinoma, melanoma, breast, prostate malignancies, and others. The higher approvals of immunotherapeutic agents have propelled the market growth.

Various Strategic initiatives undertaken by leading players are also expected to facilitate the market demand. For instance, in August 2022,  BioNTech SE and Genmab A/S expanded their strategic collaboration for the development and launch of new immune therapies for the treatment of various cancer forms. Moreover, in March 2022,  Merck & Co., Inc announced the approval of KEYTRUDA from the U.S. FDA. KEYTRUDA is an anti-PD-1 therapy for the treatment of advanced endometrial carcinoma.

However, side effects associated with immunotherapy are likely to hamper the prescription rate for cancer treatment. The available therapies are associated with several adverse effects, such as pain, insomnia, fatigue, nausea, and gastrointestinal conditions. These adverse effects impact the overall quality of life of patients and the management of these adverse effects incurs extra costs. In addition, prolonged consumption of immunotherapeutic drugs may cause severe damage to the organs and increase the incidence of organ failure cases.

The lung cancer segment dominated the market in 2021. The rising prevalence of lung malignancies, increasing adoption of immunotherapy, increase in awareness programs, and presence of a robust pipeline of investigational candidates are some of the key factors expected to drive the segment’s growth. Furthermore, rising product approval and product launch fueling the demand forward. For instance, in October 2021, the U.S. FDA approved Tecentriq (atezolizumab) for the treatment of stage II and stage III NSCLC.

The breast cancer segment held the second largest share owing to the high prevalence of the disease, ongoing research activities, and rising investments by leading players to develop novel therapeutics for breast malignancies are expected to accelerate segment expansion. However, the prostate cancer segment is anticipated to experience the fastest growth rate over the forecast period.

Market players are adopting strategies such as new product development, merger & acquisition, and partnership to increase their market share. For instance, in February 2022, Medigene AG and BioNTech SE collaborated to develop T-cell receptor-based immunotherapies for oncology disorders. Some prominent players in the cancer immunotherapy market include:

  • Pfizer Inc.
  • AstraZeneca
  • Merck & Co., Inc
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Genentech, Inc (Roche)
  • Novartis AG
  • Lilly
  • Johnson & Johnson Services, Inc
  • Immunocore, Ltd

In 2021, North America led the overall market in terms of revenue due to the presence of a large number of leading players coupled with various Strategic initiatives undertaken by them. Moreover, the increase in disease prevalence and the presence of various government and non-government organizations that promote research activities for cancer immunotherapy, and the increasing approval of novel drugs are fueling the regional market growth. For instance, in April 2022, the U.S. FDA approved Opdivo (nivolumab) for the treatment of NSCLC in adult patients. Asia Pacific is projected to witness the fastest growth rate over the forecast period. The increase in the geriatric population, a large patient base of a targeted diseases, and improving healthcare infrastructure are some of the primary factors driving the growth. Moreover, the rising regulatory approvals of immune therapies in the region are also contributing region’s expansion. For instance, during 2020-2022, the National Medical Products Administration of China approved Pembrolizumab and Durvalumab for the treatment of esophageal cancer and SCLC.

Source : https://www.grandviewresearch.com/industry-analysis/cancer-immunotherapy-market

mRNA Therapeutics Market Size & Market Analysis

The global mRNA therapeutics market size is expected to reach USD 37.76 billion by 2030. It is expected to expand at a CAGR of 1.7% from 2022 to 2030. One of the main factors propelling the market growth is the rising incidence of chronic and infectious diseases like diabetes, HIV, cancer, and CVDs.

mRNA therapeutics Market Size & Market Analysis

The growing need for therapeutic drugs and vaccinations to combat viral illnesses like Ebola, influenza, HIV, and most recently COVID-19 is expected to fuel industry growth. The COVID-19 virus has been the focus of numerous government organizations and vaccine producers, and it is anticipated that this will accelerate market expansion.

mRNA therapeutics Market Size & Market Analysis

Furthermore, the availability of vaccination doses around the world is projected to increase during the forecast period as a result of multiple suppliers using novel techniques, such as combining the phase 1 and phase 2 clinical trial stages and obtaining regulatory clearances more quickly from health agencies, thus contributing to the industry growth. With the use of cutting-edge technologies, mRNA vaccines and therapeutics are generated in comparison to conventional medications. These products are less expensive to produce, more powerful against infections, and have enhanced immunogenicity. A favourable outlook for market expansion is also being created by advancements in the compositions of lipid nanoparticles for in-vivo systemic delivery of mRNA.
For instance, in March 2022, The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) launched a phase 1 clinical trial to assess three potential HIV vaccines using a messenger RNA (mRNA) platform due to its active component and direct the cells to make a protein (or perhaps a protein fragment) that stimulates an immune response using artificial mRNA created in a lab, which enhances the vaccine with more specificity as well as robust stability. Thus, it will increase the demand and further boost the industry growth.
As another significant growth-inducing element, pharmaceutical firms are spending on mRNA technology since they can combine numerous molecules into a therapeutic drug. The market is expected to be driven by additional factors, such as significant biotechnology-related research and development (R&D) initiatives and advancements in medical technology. For instance, Moderna and AstraZeneca are working together on a myocardial ischemia therapy using mRNA (a form of cardiac disease that develops when there is a decrease in blood flow to the heart, depriving the heart muscle of necessary oxygen). Similarly, mRNA treatments for heart disease are also being tested by Arcturus Therapeutics. Such investments are likely to supplement the market growth in the coming years.

mRNA therapeutics Market Size & Market Analysis

The COVID-19 pandemic is anticipated to positively impact the industry growth. The COVID-19 vaccine is one of the diseases for which the mRNA technology is being used. In addition to its predominant use in cancer or metastasis cancer therapy, the COVID-19 vaccine is the main factor driving the market for mRNA. The mRNA firms are working hard to create COVID-19 vaccines for the next generation due to the coronavirus mutation and the potential spread of virus variants. For instance, in June 2022, The Food and Drug Administration approved the Moderna COVID-19 Vaccine and also the Pfizer & BioNTech COVID-19 Vaccine for use in children as young as 6 months old as COVID-19 preventative measures. As a result, the usage of these technologies is projected to increase during the COVID-19 pandemic and result in industry growth.
Additionally, there has been a discernible trend toward consolidation over the past few years, with players forming strategic alliances to support current R&D projects. For instance, in February 2021, building on their current partnership, GlaxoSmithKline plc and CureVac N.V. announced a new USD152.36 million agreement to create COVID-19 next-generation mRNA vaccines with the possibility for a multi-valent strategy to address numerous developing variations in a single vaccination. As additional mRNA-based therapeutic / vaccine leads exhibit proof-of-concept, go through clinical testing, and eventually hit the market, the opportunity for stakeholders involved in this specialized industry segment is likely to experience a significant increase in the predicted future.

List of main Players in the mRNA Therapeutics Market Size & Market Analysis :

Moderna, Inc.
BioNTech SE
CureVac N.V.
Arcturus Therapeutics
Translate Bio, Inc.
GSK plc.
Argos Therapeutics Inc.
Sangamo Therapeutics, Inc.
Pfizer Inc.
AstraZeneca plc.
CRISPR Therapeutics AG

Source : https://www.researchandmarkets.com/reports/5644939/global-mrna-therapeutics-market-size-share-and#:~:text=The%20global%20mRNA%20therapeutics%20market%20size%20is%20expected,infectious%20diseases%20like%20diabetes%2C%20HIV%2C%20cancer%2C%20and%20CVDs.

Metastasis Cancer Treatment Market size & Market Analysis

The global Metastasis Cancer Treatment Market size in terms of revenue was worth of $63.18 Billion in 2020 and is expected to reach $161.67 Billion in 2027, growing at CAGR of 12.3% from 2021 to 2027.

Metastasis Cancer Treatment Market size & Market Analysis

Metastasis cancer represents the advanced form of cancer, which occurs when the cancer cells start spreading from the site of origin to different parts of the body. Treatment for Metastasis cancer aims to slow the expansion or spread of the cancer. Treatment depends on the sort of cancer, where it started, the dimension and location of the metastasis and other factors. The treatment for Metastasis cancer is often different from the ones used for a normal tumor. Treatment of Metastasis cancer is often not curable and is mainly focused on providing relaxing care. Several manufactures are investing in oncology market and are making vigorous efforts for the supply of cost-effective cancer treatment drugs used in chemotherapy, radiation therapy and hormone therapy. Patients all over the world are looking forward for advanced cancer therapy drugs to capture their condition, which is turn, is increasing the adoption rate of the Metastasis cancer treatment drugs.

Metastasis occurs when cancer progresses to different parts of the body from where it originated and it is the culmination of neoplastic progression. Cancer metastasis is a major challenge in cancer treatment as it is difficult to diagnose and treat. Metastasis accounts for 90% of cancer associated mortality and only a small number of patients with metastatic cancer can be treated with conventional strategies such as chemotherapy, radiotherapy and surgical removal.

Metastasis Cancer Treatment Market size & Market Analysis

Increasing focus on development of new strategies to prevent metastasis, rapid adoption of stem cells and oncolytic viruses to treat metastatic cancer, and growing caseload of cancer across the globe are some key factors expected to drive market revenue growth over the forecast period. In addition, increasing research and development activities to understand molecular mechanisms of metastasis and rising number of clinical trials to develop personalized treatments that can specifically target metastases are some other key factors expected to contribute revenue growth of the market going ahead.

The major drivers for the global Metastasis cancer treatment market growth are rising prevalence of cancer and high medical needs of patients who have Metastasis cancer. Rising prevalence of Metastasis cancer is one of the major factors expected to drive the growth of the global Metastasis cancer treatment market. It is estimated that metastasis is responsible for about 90% of cancer deaths. This estimate has changed little in more than 50 years, according to National Center for Biotechnology Information. The increasing cancer burden is due to several factors, including population growth and ageing as well as the changing prevalence of certain causes of cancer linked to social and economic development. Breast cancer is the second most common cause of death from cancer in 6% women. It is estimated that 42,690 people will die from breast cancer, according to American Society of Clinical Oncology. Metastasis breast cancer will cause the vast majority of those deaths. However, high cost of Metastasis cancer treatment may hamper the growth of this market. In spite of that, increasing number of pharmaceutical, biotechnology and diagnostic companies are focusing on research and development of innovative oncology medicines to provide advanced treatment which may create more opportunities for the further growth of the market.

Metastasis Cancer Treatment Market size & Market Analysis

Metastasis is the major reason for treatment failure in cancer patients and accounts for majority of cancer-related deaths. Metastasis also causes treatment failure even in tumors that are sensitive to chemotherapy or radiotherapy. Metastatic tumors are difficult to treat with conventional therapy due to their anatomically diffuse localization and resistance to cytotoxic agents. Rapid technological advancements in imaging and cancer cell identification have significantly improved understanding of cancer metastasis. Treatment of metastatic cancer primarily aims to slow the growth or spread of cancer and typically requires systemic therapy or oral or intravenous medications to reach cancer cells throughout the body.

Other treatment approaches include immunotherapy, radiation therapy, surgical intervention, or a combination of these treatments. In addition, clinical trials offer access top novel treatment approaches that can prove to be more appropriate and effective as compared to standard of care options. Various therapeutic options are available to ease side effects and enhance quality of life of patients even after metastatic cancer has stopped responding to treatments. Development of new strategies to manage and treat metastatic cancer and advancements in stem cell therapy are some factors expected to drive market revenue growth over the forecast period.

However, difficulties associated with the treatment of metastatic cancer, high costs of cancer treatment, and resistance of metastatic cells to conventional treatment approaches and cytotoxic agents are some key factors expected to restrain market growth to a certain extent over the forecast period. In addition, lack of knowledge regarding metastatic processes, recurrence of cancer, and systemic side effects of treatment are some other factors expected to hamper market growth to a certain extent over the forecast period.  

North America is the highest revenue generating market for Metastasis cancer treatment solutions. The rate of diagnosis is high in this region due to advances healthcare infrastructure and awareness among the people. According to American cancer society; in 2016; there were approximately 3.5 million women living with an antiquity of breast cancer in the United States. More than 16.9 million Americans with a history of cancer were alive on January 1st, 2019, and this number is projected to grow to more than 22.1 million by January 1st, 2030, according to Carevive Systems, Inc. Europe is second largest region for this market due to rising Advancements in immune-oncology and precision medicine. Immense scientific innovation in the field of oncology has resulted in higher regulatory approval rates of cancer treatment drugs used in chemotherapy, radiation therapy, and hormone therapy, among others in this region. In 2017, more than 3,500 radiation therapy machines were used by hospitals and providers of ambulatory health care in the European Union (EU). The performance of breast-protection surgery has increased, and the use of neoadjuvant therapy to downstage locally advanced breast cancer has become more common in the Asia–Pacific region.

Metastasis Cancer Treatment – Main Players :

List of main players in the Global Metastasis Cancer Treatment Market size & Market Analysis :

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • BRISTOL-MYERS SQUIBB COMPANY
  • Eli-Lilly and Company
  • Hoffmann-La Roche AG
  • JOHNSON & JOHNSON
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • SANOFI

Source Metastasis Cancer Treatment Market size & Market Analysis : https://brandessenceresearch.com/healthcare/metastasis-cancer-treatment-market

Liposome Drug Delivery Market Size & Market Analysis

The global liposome drug delivery market is anticipated to grow with a CAGR of 10.69% over the forecast period, 2022 – 2031. The market is estimated to garner a revenue of near to USD 11980 Million by the end of 2031, up from a revenue of more than USD 4350 Million in the year 2021.

The liposomal doxorubicin segment, by the end of 2031, is projected to garner the largest revenue of about USD 3220 Million. Additionally, in the year 2021, the segment generated a revenue of near to USD 1140 Million. The market in North America, by the end of 2031, is projected to garner the largest revenue of close to USD 4430 Million. Additionally, in the year 2021, the market in the region generated a revenue of around USD 1690 Million.

Liposome Drug Delivery Market Size & Market Analysis

The global liposome drug delivery market is anticipated to grow with a CAGR of 10.69% over the forecast period, 2022 – 2031. Factors such as the surge in concern for the rising prevalence of cancer around the globe, along with the increasing adoption of advanced drug delivery systems for the treatment of the disease are anticipated to drive the growth of the market in the coming years.

Additionally, factors such as the surge in use of liposomes as drug delivery systems, and the numerous benefits associated with the use of liposomes for drug delivery in cancer treatment are also projected to boost the market growth during the forecast period. The market is estimated to garner a revenue of near to USD 11980 Million by the end of 2031, up from a revenue of more than USD 4350 Million in the year 2021.

Liposomal Drug Delivery Market Size & Market Analysis

The global liposome drug delivery market is segmented by numerous segments, which include segmentation by product, technology, application, and by region. By product, the market is segmented by product into liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. The liposomal doxorubicin segment, by the end of 2031, is projected to garner the largest revenue of about USD 3220 Million. Additionally, in the year 2021, the segment generated a revenue of near to USD 1140 Million.

On the basis of regional analysis, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America, by the end of 2031, is projected to garner the largest revenue of close to USD 4430 Million. Additionally, in the year 2021, the market in the region generated a revenue of around USD 1690 Million.

Major players in the Liposome Drug Delivery Market Size & Market Analysis :

  • Spectrum Pharmaceuticals Inc.
  • Gilead Sciences Inc.
  • Celsion Corporation
  • Ipsen Pharma
  • Pacira Pharmaceuticals Inc.
  • Novartis AG
  • CordenPharma International
  • FUJIFILM Toyama Chemical Co. Ltd.
  • Takeda Pharmaceutical Company Limited
  • Johnson & Johnson Services Inc.
  • Astellas Pharma Inc.
  • Elan Pharmaceuticals (Perrigo Company plc)
  • Merrimack Pharmaceuticals Inc.
  • Janssen Pharmaceuticals Inc.

Liposome Drug Delivery Market Size & Market Analysis

Source : https://www.researchandmarkets.com/reports/5624580/global-liposome-drug-delivery-market-analysis

Bladder Cancer Drugs Market size & Market analysis

The global bladder cancer drugs market is expected to grow from $1.98 billion in 2021 to $2.35 billion in 2022 at a compound annual growth rate (CAGR) of 19.1%. The market is expected to reach $4.45 billion in 2026 at a CAGR of 17.3%.

Bladder Cancer Drugs Market size & Market analysis

North America is the largest region in the bladder cancer drugs market in 2021. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The American Cancer Society’s estimates for bladder cancer in the United States for 2021 are about 83,730 new cases of bladder cancer. In addition, the rising geriatric population, unhygienic sedentary lifestyle, and smoking habits are increasing the prevalence of most cancer cases.

When the cells that make up the urinary bladder begin to proliferate out of control, bladder cancer develops. More cancer cells can form a tumor and spread to other places of the body as time goes on. The bladder wall is made up of multiple layers. Each layer is made up of many cell types. The urothelium or transitional epithelium, which lines the inside of the bladder, is where most bladder malignancies begin. Cancer progresses to a higher stage, gets more advanced, and is more difficult to cure when it spreads into or through the other layers of the bladder wall. Cancer may spread outside the bladder and into neighboring structures over time. It could spread to nearby lymph nodes or other organs.

Bladder Cancer Drugs Market size & Market analysis

The most frequent type of bladder cancer is urothelial carcinoma, also known as transitional cell carcinoma (TCC). Urothelial carcinoma is virtually always been the cause of bladder cancer. Squamous cell carcinomas account for about 1% to 2% of bladder malignancies in the United States. The cells, when viewed under a microscope, resemble the flat cells present on the skin’s surface. Squamous cell carcinomas of the bladder are almost always invasive. Adenocarcinomas make up roughly 1% of all bladder cancers. These cancer cells have a lot in common with colon cancer gland-forming cells. Almost of bladder adenocarcinomas are invasive. Small-cell carcinomas account for less than 1% of bladder cancers. They begin in neuroendocrine cells, which are nerve-like cells. These cancers grow quickly and require chemotherapy, similar to that used to treat small cell carcinoma of the lung. Sarcomas begin in the bladder’s muscle cells, but they are extremely rare. Soft Tissue Sarcoma and Rhabdomyosarcoma have more information. These less common kinds of bladder cancer (apart from sarcoma) are treated similarly to TCCs, especially in the early stages, but alternative drugs may be used if chemotherapy is required.

Major organizations are investing on the research to utilize nano-technology as a means to deliver drugs into the human body. nanotechnology is the design, characterization, production, and application of devices, structures and systems by controlled manipulation of size and shape at the nanometer scale.

This method of delivery helps doctors to offer a simple and effective way of treating bladder cancer in their patients, due to the fact that the nanoparticles used in the treatment can attack the cancerous cells directly without harming the surrounding cells.

Bladder Cancer Drugs Market size & Market analysis

Source : https://www.researchandmarkets.com/reports/5559826/bladder-cancer-drugs-global-market-report-2022

Coronavirus Covid19 Covid-19 Diagnostics Market Size & Market Analysis

The global COVID-19 diagnostics market size was valued at USD 97.4 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.7% from 2022 to 2030. The market is driven by the rising government initiatives targeted toward the implementation of mass testing.

Coronavirus Covid19 Covid-19 Diagnostics Market Size & Market Analysis

Transitioning focus of new entrants toward at-home testing and integration of advanced software has been witnessed in the past few months. This is expected to increase patient convenience in regard to time-consuming laboratory-based testing. 

The considerable increase in patient population around the world, the enormous need for speedy diagnostics, and the lack of specific drug or vaccination are the primary factors driving the market for Covid-19 diagnostics. However, a lack of awareness among developing countries about the precautions that must be taken, as well as a scarcity of diagnostic kits and medical professionals with sufficient understanding about the use of diagnostic kits for new Covid-19, are expected to stymie market expansion. Leading diagnostic kit producers, on the other hand, can benefit from a number of profitable ventures by manufacturing rapid diagnostic kits. Moreover, several local players and small startups are producing diagnostic kits and assays to take advantage of huge prospects. For example, once the National Institute of Virology confirmed its test, Mylab, India gained permission from the Drug Controller of India for manufacturing the Covid-19 diagnostic kit.

Coronavirus Covid19 Covid-19 Diagnostics Market Size & Market Analysis

The demand for COVID-19 diagnostic products is set to propel further with the increasing number of coronavirus-infected patients, particularly post the ease of lockdown across the globe. According to World meter, the total number of cases witnessed a spike with 33,556,252 patients testing positive as of 28th September 2020 to 55,961,380 patients on 17th November 2020. Despite the gradual decline expected in the number of positive patients in 2021, integration of COVID-19 tests in routine diagnostic protocols is expected to maintain the growth of the market for Covid-19 diagnostics.

Moreover, these testing programs are set to pave way for the travel industry to gear up, creating a favorable environment for the entities operating in the market for Covid-19 diagnostics. The tourism and travel industries have been most affected during this pandemic outbreak, which has led to an upsurge in COVID-19 testing initiatives post August 2020, particularly in tourism-based countries and regions. This is also expected to propel the PoC testing market penetration as these tests are able to overcome the limitations associated with traditional testing.

Complex and pure reagents, such as probes, enzymes, and primers, are crucial in conducting tests in clinical laboratories. A number of factors like a sudden increase in demand, export bans, and stockpiling have led to the shortage of these reagents. Additionally, these reagents are manufactured by limited companies, therefore leading to a shortage of supply due to insufficient production capacity. The inadequate demand-to-supply ratio of reagents worldwide is anticipated to negatively impact the overall diagnosis rate and hinder the growth of the market for Covid-19 diagnostics.

The market for Covid-19 diagnostics is divided into two segments based on technology: PCR and immunoassay. Because of the rising need for coronavirus patient diagnosis, the PCR segment is likely to rise rapidly in the near future. Furthermore, PCR is regarded as the gold standard for detecting COVID-19 infections. The immunoassay segment is expected to increase at the fastest rate throughout the forecast period, due to a rise in the need for quick serological testing for disease diagnosis. A plethora of serological kits is being developed to confirm Sars Cov 2 infections.

The services segment is estimated to dominate the market for Covid-19 diagnostics and accounted for revenue share of 47.8% in 2021. Service providers are boosting their testing capabilities by expanding technological footprints in existing labs and diagnostic centers as well as by launching new, high-capacity laboratories, which has contributed to the segment growth. Collaborations between governments, test developers, public health organizations, and private laboratories accelerate the expansion of testing capacities. 

The reagents and kits segment is expected to register a CAGR of (7.2%) from 2020 to 2030. The reduction in the number of active COVID-19 cases is responsible for the declining market growth of this segment. In response to the pandemic, companies are implementing various strategic initiatives, such as new product development and collaborations.

Coronavirus Covid19 Covid-19 Diagnostics Market Size & Market Analysis

Source : https://www.grandviewresearch.com/industry-analysis/covid-19-diagnostics-market

Coronavirus Covid19 Covid-19 Treatments Drugs Market Size & Market Analysis

The global COVID-19 Therapeutics market size was valued at US$ 10.2 Billion in 2021, and it is expected to reach US$ 25.6 Billion in 2030, record a promising CAGR of 10.7% from 2021 to 2030.

Coronavirus Covid19 Covid-19 Treatments Drugs Market Size & Market Analysis

COVID-19 is a contagious disease triggered by the most recently discovered coronavirus, which has affected millions of individuals worldwide. The coronavirus can be treated with various drugs, including corticosteroids, antivirals, monoclonal antibodies, and kinase inhibitors. In August 2021, The World Health Organization (WHO) released a report that represents Artesunate, imatinib, and infliximab are three new potential medications being investigated in the latest phase of the global Solidarity clinical trials to find effective COVID-19 therapies. Additional medicines approved for emergency use include Eli Lilly and Company’s monoclonal antibodies bamlanivimab with etesevimab; Regeneron’s casirivimab and imdevimab; GlaxoSmithKline/Vir Biotechology’s Xevudy (sotrovimab); Roche’s Actemra; Celltrion’s Regkirona; and convalescent plasma. The growth of the COVID-19 Therapeutics Market is primarily attributed the increased prevalence of COVID-19 across the globe. In the first week of January 2022, Covid-19 cases have now been recorded in over 300 million people worldwide. The United States had over 50 million confirmed cases and over 800,000 deaths, making it the Country with the highest death toll. Pharmaceutical companies are investing heavily in product research due to the rising pandemic effect, and they are focusing on the production of enhanced therapeutics that can cure the covid-19. The market is further supported by rising awareness about coronavirus and collective efforts by the pharmaceutical companies and government in the development of covid-19 therapeutic drugs.

Coronavirus Covid19 Covid-19 Treatments Drugs Market Size & Market Analysis

The prominent players in the COVID-19 Therapeutics industry include Atea Pharmaceuticals, Inc., Fulcrum Therapeutics, CytoDyn, Eli Lilly and Company, Celltrion, Shanghai Junshi Biosciences Co., Ltd., NRX Pharmaceuticals, Veru Inc., Catalent, Inc., Humanigen, Inc., Molecular Partners AG, Cipla Limited, Merck, Regeneron Pharmaceuticals, Inc., Novartis International AG, Vir Biotechnology, Brii Biosciences Limited, Revive Therapeutics Ltd., GlaxoSmithKline plc, APEIRON Biologics AG, Janssen Pharmaceuticals, Bristol Myers Squibb, Trevena Inc, Constant Therapeutics LLC, Ono Pharmaceutical Co., Ltd., Amarin Corporation plc, NeuroBo Pharmaceuticals, Inc., FUJIFILM Toyama Chemical Co., Ltd., Innovation Pharmaceuticals Inc., Bellerophon Therapeutics, Sorrento Therapeutics, PhaseBio, BioAegis Therapeutics, Pfizer, Takeda, Roivant Sciences, Celltex Therapeutics, Blade Therapeutics, A.I. Therapeutics, Inc., Marinomed Biotech AG, Synairgen, Romark Laboratories, SAb Biotherapeutics, Kiniksa Pharmaceuticals, UNION therapeutics A/S, etc.

COVID-19 Therapeutics Market Regional Analysis

In 2021, North America is expected to have the largest share of R&D in the global covid-19 therapeutics market, owing to increased government spending on drug development, growing government initiatives for covid-19 vaccine R&D, an increasing number of market players, and the implementation of favorable government initiatives in the U.S. and Canada. However, due to increased government initiatives to increase medication production and the number of research and development activities, the Asia Pacific area is predicted to grow rapidly in the target market. In June 2021, India’s pharma regulator approved the emergency use of Eli Lilly and Company India’s antibody medication combination, which is used to treat mild to moderate COVID-19 patients. The monoclonal antibody medications bamlanivimab 700 mg, and etesevimab 1400 mg have been approved by the company. Both of these medicines are utilized to treat COVID-19 patients who have mild to moderate symptoms.

The Global COVID-19 therapeutics Market Segments : Antiviral , Monoclonal Antibodies, Glucocorticoid, Anticoagulant, Nitric oxide and Other Drug Class.

Coronavirus Covid19 Covid-19 Treatments Drugs Market Size & Market Analysis

Source : https://www.bloomberg.com/press-releases/2022-01-18/global-covid-19-therapeutics-market-worth-14-6-billion-by-2022-exclusive-report-by-insightace-analytic and https://www.insightaceanalytic.com/report/global-covid-19-therapeutics-market/1184

Bispecific mAbs – Bispecific Antibodies Market Size & Market Analysis

The market is expected to reach $11.64 billion in 2026 at a CAGR of 22.7%. The global bi-specific mabs market is expected to grow from $3.80 billion in 2021 to $5.13 billion in 2022 at a compound annual growth rate (CAGR) of 34.9%.

Bispecific mAbs - Bispecific Antibodies Market Size & Market Analysis

The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges.

The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of bispecific monoclonal antibodies and related services. Bi-Specific MAbs are artificial proteins that can bind two or more antigens into a single product. Bispecific monoclonal antibodies are used to improve immune response in various medical conditions and finds its applications in the field of drug delivery and cancer immunotherapy.

Bispecific mAbs – Bispecific Antibodies Market Size & Market Analysis

The main types of bi-specific are catumaxomab (removab), blinatumomab, duligotumab, SAR 156597. Catumaxomab is a rat-mouse hybrid monoclonal antibody used to treat malignant ascites, a condition that occurs in people who have metastasizing cancer. The various product types include in vivo, in vitro that are used for the treatment of cancer, autoimmune diseases, inflammatory diseases, infectious diseases, microbial diseases and others. The bispecific monoclonal antibodies are used by hospitals, research institutes, others.

The increasing prevalence of cancer and other chronic diseases is projected to contribute to the growth of the bispecific monoclonal antibodies market over the forecast period. Bispecific monoclonal antibodies are developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Bispecific monoclonal antibodies are considered to be more effective over monoclonal antibodies (moAbs) as these target two or more tumor antigens on cells to disrupt cancer progression.

According to the World Health Organization, cancer is the leading cause of death worldwide and is responsible for around 10 million deaths in 2020. Additionally, according to the Centers for Disease Control and Prevention, chronic diseases are among the most prevalent diseases with 6 out of 10 adults suffering from at least one chronic disease in the USA. Therefore, a rising number of chronic diseases including cancer is anticipated to propel the demand for bi-specific MAbs market to treat these diseases effectively.

The availability of various alternative treatment methods for cancer is expected to limit the growth of the bispecific monoclonal antibodies market. Alternative cancer treatment therapies and methods used for the treatment of cancer including dietary treatments, acupuncture, homeopathy, and herbal remedies are gaining popularity in recent years attributed to side effects of chemotherapeutic anticancer agents.

For instance, Ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. Many of the herbs used in Ayurveda have anti-cancer properties, for example, andrographis paniculata. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source and developing nations are using the benefits of natural compounds for therapeutic purposes.

Companies in the bispecific mAbs antibodies market are increasingly investing in various strategic initiatives such as collaborations and partnerships to expand the product portfolio and geographical presence of the company.

Major players in the bi-specific MAbs or bispecific monoclonal antibodies market are

  • Johnson & Johnson
  • Novartis AG
  • Hoffmann-La Roche Ltd.
  • Novo Nordisk A/S
  • Bayer AG
  • Thermo Fisher Scientific, inc.
  • Bistro-Myers Squibb. Mylan N.V.
  • Daiichi Sankyo Company, Ltd.
  • Abbott
  • AstraZeneca
  • Eli Lilly
  • Merck & Co. inc.
  • Amgen inc.
  • Pfizer inc.
  • GlaxoSmithKline plc.
  • Roche
  • Sanofi
  • Genentech
  • Immunomedics
  • Chugai Pharmaceutical
  • EMD Serono
  • Emergent BioSolutions
  • Jounce Therapeutics
  • MarcoGenics
  • Merus
  • Neovii Biotech
  • NovImmune SA
  • OncoMed Pharmaceuticals
  • Pieris
  • Regeneron Pharmaceuticals

Bispecific mAbs – Bispecific Antibodies Market Size & Market Analysis

Source : https://www.researchandmarkets.com/reports/5553759/bi-specific-mabs-global-market-report-2022

Autoimmune Diseases Diagnostics Market Size & Market Analysis

The autoimmune disease diagnostics market was valued at USD 4,253.30 million in 2021 and is projected to reach USD 6,298.98 million by 2027 registering a CAGR of nearly 6.8% during the forecast period.

Autoimmune Diseases Diagnostics Market Size & Market Analysis

The first wave of COVID-19 pandemic has disrupted almost all areas of the health care services to some extent throughout the world. The negative impact of COVID-19 on patients with autoimmune diseases has also been recognized. According to an article titled “The impact of the COVID-19 pandemic on autoimmune diagnostics in Europe: A lesson to be learned” published in October 2021, a decrease in the number of autoantibody tests was observed in all European countries in the year 2020 compared to 2019. All autoantibody tests saw a 13% decrease, ranging from 1.4% in Switzerland to 25.5% in the United States (Greece). The decrease was most pronounced in all countries during the first wave of the pandemic (March-May 2020), with an overall decrease of 45.2% in those three months. The decrease was less pronounced(6.8%) in the second wave of the pandemic (October-December 2020).

The rising autoimmune diseases is the major factor behind the market growth. According to scientists at the National Institutes of Health and their collaborators, autoimmunity, a condition in which the body’s immune system reacts with components of its own cells, appears to be increasing in the United States. Also, as per the article published in January 2022, Autoimmune diseases are becoming more prevalent around the world. The global spread of Western diets is linked to higher levels of autoimmune disease. As per the same source, Tens of millions of people develop autoimmune diseases in the US alone, and the number of cases has been increasing in recent decades. Thus, the increasing autoimmune diseases is driving the market growth.

Autoimmune Diseases Diagnostics Market Size & Market Analysis

The rising awareness about autoimmune diseases through programs of research, education, support, and advocacy is a key factor boosting the usage rates of autoimmune disease diagnostics, globally. Government organizations and NGOs aims to increase awareness about the socioeconomic impact of autoimmunity through fostering and facilitating collaboration in the areas of education, public awareness, research, and patient services in an effective, ethical, and efficient manner. The other factors, such as improved laboratory automation, partnerships with physicians and clinical laboratories, and technological advancements, are driving the autoimmune disease diagnostics market. However, the slow turnaround time of the diagnosis and high frequency of false results are hindering the growth of the autoimmune disease diagnostics market.

Autoimmunity involves the loss of normal immune homeostasis, as the organism produces an abnormal response to its own tissue. Autoimmune diseases generally involve the presence of self-reactive T cells, autoantibodies, and inflammation. Diagnosis of potential autoimmune diseases is very difficult, because not one laboratory test alone can produce diagnosis results for the disease. The diagnosis can be useful in the management of patients suffering from autoimmune diseases and help in providing a prognosis or indicating the severity of organ involvement or damage. The Autoimmune Disease Diagnostics Market is Segmented by Disease Type ( Systemic Autoimmune Disease​ ( Rheumatoid Arthritis, Psoriasis, Systemic Lupus Erythematosus (SLE), Multiple Sclerosis, Other Systemic Autoimmune Diseases) and Localized Autoimmune Disease (Inflammatory Bowel Disease, Type 1 Diabetes, Thyroid, and Other Localized Autoimmune Diseases​), Diagnosis Type (Antinuclear Antibody Tests​, Autoantibody Tests​, Complete Blood Count (CBC)​, C-reactive Protein (CRP)​, Urinalysis​, Others tests), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). 

Autoimmune Diseases Diagnostics Market Size & Market Analysis

Source : https://www.mordorintelligence.com/industry-reports/global-autoimmune-disease-diagnostics-market